Gateway Investment Advisers LLC grew its holdings in Shire PLC (NASDAQ:SHPG) by 24.3% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 74,398 shares of the biopharmaceutical company’s stock after acquiring an additional 14,537 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Shire were worth $11,541,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of SHPG. Quadrant Capital Group LLC increased its position in shares of Shire by 3.7% during the second quarter. Quadrant Capital Group LLC now owns 1,839 shares of the biopharmaceutical company’s stock worth $280,000 after purchasing an additional 66 shares in the last quarter. Bayesian Capital Management LP grew its holdings in Shire by 3.9% in the 2nd quarter. Bayesian Capital Management LP now owns 3,947 shares of the biopharmaceutical company’s stock valued at $652,000 after buying an additional 147 shares in the last quarter. ETRADE Capital Management LLC lifted its stake in shares of Shire by 2.6% in the 2nd quarter. ETRADE Capital Management LLC now owns 6,218 shares of the biopharmaceutical company’s stock valued at $1,028,000 after purchasing an additional 160 shares during the last quarter. L & S Advisors Inc lifted its stake in shares of Shire by 6.3% in the 2nd quarter. L & S Advisors Inc now owns 2,886 shares of the biopharmaceutical company’s stock valued at $477,000 after purchasing an additional 171 shares during the last quarter. Finally, Roberts Glore & Co. Inc. IL lifted its stake in shares of Shire by 10.2% in the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 2,218 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 206 shares during the last quarter. Institutional investors and hedge funds own 20.23% of the company’s stock.

Shire PLC (SHPG) opened at $144.99 on Friday. The stock has a market capitalization of $43,420.00, a P/E ratio of 27.31, a P/E/G ratio of 0.78 and a beta of 1.59. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.52 and a current ratio of 0.98. Shire PLC has a 12 month low of $137.17 and a 12 month high of $192.15.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.17 EPS. analysts expect that Shire PLC will post 15 earnings per share for the current fiscal year.

Several research firms recently issued reports on SHPG. BidaskClub lowered Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies reiterated a “hold” rating and issued a $160.00 price objective on shares of Shire in a report on Friday, October 27th. Royal Bank of Canada reiterated a “buy” rating on shares of Shire in a report on Thursday, November 16th. Cantor Fitzgerald set a $222.00 price objective on Shire and gave the company a “buy” rating in a report on Wednesday, January 3rd. Finally, Liberum Capital reiterated a “hold” rating on shares of Shire in a report on Wednesday, December 20th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the stock. Shire currently has a consensus rating of “Hold” and an average price target of $212.18.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/01/20/shire-plc-shpg-stake-increased-by-gateway-investment-advisers-llc.html.

About Shire

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.